Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Operating Leases (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Operating Leases for 4 consecutive years, with $15.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 57.42% year-over-year to $15.0 million, compared with a TTM value of $15.0 million through Sep 2025, down 57.42%, and an annual FY2024 reading of $29.9 million, down 34.53% over the prior year.
  • Operating Leases was $15.0 million for Q3 2025 at Atara Biotherapeutics, down from $15.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $64.0 million in Q2 2022 and bottomed at $15.0 million in Q3 2025.
  • Average Operating Leases over 4 years is $40.3 million, with a median of $42.2 million recorded in 2024.
  • The sharpest move saw Operating Leases surged 214.66% in 2023, then crashed 60.14% in 2025.
  • Year by year, Operating Leases stood at $58.1 million in 2022, then fell by 21.31% to $45.7 million in 2023, then crashed by 34.53% to $29.9 million in 2024, then tumbled by 49.84% to $15.0 million in 2025.
  • Business Quant data shows Operating Leases for ATRA at $15.0 million in Q3 2025, $15.4 million in Q2 2025, and $26.7 million in Q1 2025.